Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Connect Biopharma Reports Positive Phase 1 Data and Announces Initiation of Phase 1b Study in Patients with Atopic Dermatitis for Novel IL-4Rα Antibody CBP-201


News provided by

Connect Biopharmaceuticals

06 May, 2019, 09:00 GMT

Share this article

Share toX

Share this article

Share toX

TAICANG, SUZHOU, China, May 6, 2019 /PRNewswire/ -- Connect Biopharma today announced that it has successfully completed a phase 1 single ascending dose (SAD) study of its novel IL-4Rα antibody, CBP-201. The randomized, double-blind, placebo-controlled study, conducted in Melbourne, Australia, evaluated the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of CBP-201 in 40 healthy adults. CBP-201 was administered by subcutaneous (SC) injection (75 mg, 150 mg, 300 mg, 600 mg) or intravenously (300 mg).

In this study CBP-201 demonstrated rapid and sustained immune modulation activity after a single dose.  Significant reduction in serum levels of thymus activation and regulated chemokine (TARC/CCL17), a biomarker elevated in atopic dermatitis and other Th2 inflammatory diseases, was observed across all five dose groups (p<0.001 vs. placebo). On average, the decrease in serum TARC occurred as early as Day 3 and was maintained through Day 42 post dosing.

High and sustained serum CBP-201 concentrations were achieved with the expected greater than dose-proportional exposure. Bioavailability was 89% for the 600 mg SC dose. At the 300 mg SC and 600 mg SC doses, serum CBP-201 concentrations on Day 56 were well above the drug concentrations that achieved full blockade of IL-4Rα in human peripheral blood mononuclear cells (PBMC).

CBP-201 was very well tolerated. No serious adverse event (SAE) was observed at any dose level through 12 weeks of post-treatment follow-up (final study visit). Treatment emergent adverse events (AE) occurred in 80% and 70% of subjects who received CBP-201 and Placebo, respectively, and were all mild to moderate in intensity. Treatment related AEs occurred in 36.7% and 60% of subjects who received CBP-201 and Placebo, respectively. The most common AEs were headache, dizziness, and upper respiratory tract infection.

"We are extremely pleased that CBP-201 exhibited excellent tolerability along with potent biomarker activity in this first-in-human study. The prolonged biomarker activity after a single dose is consistent with a favorable PK profile and high potency," commented Jeffery White, MD., Chief Medical Officer of Connect Biopharma. "We believe the PK and PD data support the potential for once every four weeks dosing which will be of significant benefit to patients and caregivers and we look to confirm this more convenient dosing regimen in future trials. We have initiated a Phase 1b study in patients with moderate to severe atopic dermatitis with topline data anticipated in Q4 2019."

"We are thrilled that another drug candidate that emerged from our Immune Modulation Technology Platform has shown potent and sustained biomarker activity in the clinical setting," added Dr. Zheng Wei, co-founder and CEO of Connect Biopharma. "CBP-201 blocks a central pathway of Th2 inflammation by suppressing the activities of both IL-4 and IL-13. Abundant preclinical and clinical studies showed that simultaneous blockade of both IL-4 and IL-13 has the strongest effect on an array of Th2 inflammatory diseases. Our data continue to demonstrate that CBP-201 has the potential to be best in class and support our plan to move forward aggressively with its clinical development."

About CBP-201

CBP-201 is an extremely potent monoclonal antibody against IL-4Rα. IL-4Rα is a cell surface protein required for the signaling of both IL-4 and IL-13, two key Th2 pro-inflammatory cytokines with significant overlapping biological activities. CBP-201 blocks IL-4Rα signaling induced by IL-4 and IL-13 with an IC50 of 38.2 pM and 45.8 pM, respectively. CBP-201 inhibits TF-1 cell proliferation induced by IL-4 and IL-13 with an IC50 of 55.6 pM and 67.4 pM, respectively. CBP-201 was discovered internally using Connect Biopharma's Immune Modulation Technology Platform, and is under clinical development to treat atopic dermatitis and other Th2 inflammatory diseases with high unmet needs.

About Connect Biopharma

Connect Biopharma is a China-based global clinical-stage company focused on discovery and development of novel immune modulators for the treatment of autoimmune diseases and inflammation. Our Immune Modulation Technology Platform is a high-throughput screening platform built on the biology of T cell function, which rapidly identifies molecules that target clinically-validated disease pathways.

Our lead drug candidate is CBP-307, an orally-active, next-generation S1P1 and S1P5 (a G-protein coupled receptor-GPCR) modulator for the treatment of a range of autoimmune disorders, including inflammatory bowel disease, psoriasis, multiple sclerosis and other autoimmune diseases.  We have completed two phase 1 randomized, double-blind, placebo-controlled studies that assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of CBP-307. In these studies, CBP-307 exhibited an excellent safety profile and potent T cell modulation activity as well as optimal pharmacokinetic and pharmacodynamic profiles, demonstrating best-in-class potential. Two phase 2 studies are currently underway to evaluate the efficacy and safety of CBP-307 in patients with moderate-to-severe ulcerative colitis and moderate-to-severe Crohn's disease.

Our second drug candidate is CBP-201, a novel monoclonal antibody that targets IL-4Rα, a receptor subunit required for IL-4 and IL-13 signaling, and blocks a central pathway in Th2 inflammation. CBP-201 is in clinical development for the treatment of atopic dermatitis and other allergic inflammatory diseases.

Additional immune modulators in our pipeline include CBP-174, CBP-233, and CBP-312. For more information about our pipeline, please visit www.connectbiopharm.com

Media Contact:
Chris Song
csong@connectpharm.com

Related Links

http://www.connectbiopharm.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.